In summary, our study not only reveals for the first time the significant therapeutic potential of pyrotinib combined with oxaliplatin in targeting EGFR-high CN GC, but also reveals the functional role of the EGFR/GRP78/ATF4/CHOP axis in anti-EGFR therapeutic strategies. This evidence concerns the gene HSPA5 and gastric cancer.